Aegerion Pharmaceuticals, Inc.' Lomitapide Receives Orphan Drug Designation in Japan for the Treatment of Homozygous Familial Hypercholesterolemia

Published: Sep 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the company has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for lomitapide for the treatment of homozygous familial hypercholesterolemia (HoFH).

Help employers find you! Check out all the jobs and post your resume.

Back to news